Acme United (ACU) Stock Surges After Q2 2026 Earnings Beat Driven by MyMedic Integration

• Acme United (ACU) reported second-quarter 2026 earnings per share of $1.22, significantly beating the consensus estimate of $0.81.
• The company posted revenue of $62.7 million, surpassing forecasts of $58.1 million and marking a 16% year-over-year sales increase.
• MyMedic acquisition integration and 8% organic growth in the core business drove the robust financial performance.
• Gross margins expanded to 42.6%, up from 41.0% in the prior year period, indicating improved operational efficiency.
• The stock surged approximately 11.92% following the release, reaching near its 52-week high of $51.88.

Acme United Corporation delivered a decisive earnings beat for the second quarter of 2026, demonstrating strong execution in integrating its recent strategic acquisitions. The reported earnings per share of $1.22 exceeded market expectations by over 50%, reflecting a significant shift in profitability dynamics for the fiscal year . Revenue reached $62.7 million, outpacing the $58.1 million consensus estimate by nearly 8% . This performance was primarily fueled by the successful integration of MyMedic, which contributed substantial sales volume alongside 8% organic growth in the company's core business lines .

The financial results highlight a clear acceleration in top-line growth compared to previous quarters. Historical data indicates that Acme United exhibits a strong seasonal business model, with revenues typically peaking in the fiscal June quarter. In June 2024, revenues surged to $55.425 million, and this seasonal strength is projected to continue into June 2025 and beyond . The Q2 2026 results align with this historical pattern, suggesting that the company is leveraging its seasonal demand effectively while benefiting from new revenue streams .

How Is Acme United Managing Tariff Pressures and Margins?

A critical component of Acme United's Q2 2026 performance was the expansion of gross margins to 42.6%, an improvement from 41.0% in the prior year period . This margin expansion indicates improved pricing power or cost efficiencies within the company's operational structure . CEO Johnsen highlighted expectations for continued margin recovery through the remainder of the year . This outlook is predicated on the easing of tariff pressures and the gradual replacement of higher-tariff inventory with lower-cost stock .

However, the company has faced headwinds from tariffs and freight costs that have impacted profitability in earlier periods. In the period ending March 31, 2024, net income dropped significantly despite growth in operating income, indicating substantial pressure from non-operating factors or tax liabilities. The current strategy of replacing higher-tariff inventory is designed to mitigate these past pressures and stabilize long-term profitability . Investors are monitoring this transition closely to ensure that cost savings are fully realized and translated into net income growth .

What Are the Key Risks and Future Outlook for ACU?

Despite the strong Q2 results, several risk factors remain for investors to consider. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, which could potentially impact net income if not managed effectively . Additionally, the company faces ongoing headwinds from currency fluctuations and uneven geographic performance . The Canadian market, in particular, is currently lagging behind other regions, which may constrain overall growth .

Looking ahead, Acme United is focused on expanding MyMedic's distribution beyond direct-to-consumer channels into mass retail . This strategic move is expected to drive strong fourth-quarter profitability driven by seasonal demand . The company maintains a consistent dividend policy, with the quarterly dividend increased to $0.16 per share in 2026. This represents a steady increase from $0.13 in 2022, reflecting a stable capital allocation strategy focused on returning cash to shareholders . The current dividend yield stands at approximately 1.32%, indicating a modest but reliable income profile for investors .

Acme United's balance sheet remains robust, with a current ratio of 3.23, significantly higher than the industry average of 2.34. This suggests a strong ability to meet short-term obligations and a low-volatility profile, with a beta of 0.49 compared to the broader market . While operational efficiency metrics show some variation relative to peers, the company's consistent dividend growth and strong liquidity position provide a stable foundation for future performance . Investors should continue to monitor the company's ability to manage SG&A expenses and integrate MyMedic into broader retail channels as key indicators of sustained growth .